What are the results in using BCG in bladder cancer?

Bacillus Calmette-Guerin therapy: Bacillus Calmette-Guerin (BCG) is the main intravesical immunotherapy for treating early-stage bladder cancer. BCG is a germ that is related to the one that causes tuberculosis (TB), but it doesn't usually cause serious disease. read more

BCG therapy also reduces the risk of recurrence, and ongoing maintenance therapy with BCG reduces the risk of progression in patients with high-grade non–muscle invasive bladder cancer. The classic appearance of carcinoma in situ as a flat, velvety patch. read more

The patients included in this prospective study were drawn from a population-based bladder cancer cohort consisting of 78% (563/721) of all newly diagnosed bladder-cancer patients in the Stockholm county, Sweden during 1995–1996, as previously described . read more

Bacillus Calmette-Guerin therapy: Bacillus Calmette-Guerin (BCG) is the main intravesical immunotherapy for treating early-stage bladder cancer. BCG is a germ that is related to the one that causes tuberculosis (TB), but it doesn’t usually cause serious disease. BCG is put directly into the bladder through a catheter. The body’s immune system cells are attracted to the bladder and activated by BCG, which in turn affects the bladder cancer cells. read more